BANK VONTOBEL/CALL/BIOGEN IDEC/330/0.1/17.01.25

BANK VONTOBEL/CALL/BIOGEN IDEC/330/0.1/17.01.25 Stock

DE000VM9C080

Real-time Boerse Frankfurt Warrants 04:33:22 2024-06-03 EDT
0.28 ^EUR	0.00%

1 month	+32.08%
3 months	-15.15%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BIOGEN INC.

Chart BANK VONTOBEL/CALL/BIOGEN IDEC/330/0.1/17.01.25

Latest news about BIOGEN INC.

NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc.	05-31	BU
Biogen: Brussels grants marketing authorization for Charcot disease	05-31	CF
Disaster averted	05-31
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors	05-30	BU

More news

Quotes 5-day view

Date	Price	Change
24-06-03	0.28	0.00%
24-05-31	0.28	+7.69%
24-05-30	0.26	-3.70%
24-05-29	0.27	-18.18%
24-05-28	0.33	+43.48%

Real-time Boerse Frankfurt Warrants

Last update June 03, 2024 at 04:33 am

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	BIOGEN INC.
Issuer	Vontobel
WKN	VM9C08
ISIN	DE000VM9C080
Date issued	2024-01-30
Strike	330 $
Maturity	2025-01-17 (229 Days)
Parity	10 : 1
Emission price	0.79 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	1.41 €
Lowest since issue	0.109 €
Spread	0.03 €
Spread %	9.68%

Company Profile

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.

Sector

More about the company